Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
minotaURO: Pembrolizumab beyond RECIST progression with metronomic cyclophosphamide in metastatic urothelial carcinoma
2021-006501-30Phase 2Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Nov 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and cyclophosphamide in transitional cell carcinoma (TCC) and urothelial carcinoma (UC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Non progressive rate at 6 months. Started Nov 2022; status: active.
02
Drugs
pembrolizumabcyclophosphamide
03
Conditions
transitional cell carcinoma (TCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2021-006501-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006501-30.